Nordic Nanovector ASA: The Annual General Meeting held

Oslo, Norway, 28 April 2022

The Annual General Meeting (the “AGM”) of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 28 April 2022 in Oslo, Norway.

All proposals were resolved by the AGM as presented in the notice convening the AGM distributed on 6 April 2022. The complete minutes of the AGM are attached to this release, and are available on www.nordicnanovector.com.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: [email protected]

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: [email protected]

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases. Nordic Nanovector's lead clinical-stage candidate is Betalutin^®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 27 billion by 2029. Nordic Nanovector retains global marketing rights to Betalutin^® and intends to actively participate in the commercialisation of Betalutin^® in the US and other major markets. Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.